Journal article icon

Journal article

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Abstract:

PURPOSE: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. EXPERIMENTAL DESIGN: This phase II, open-label, multicenter, randomized, parallel-group study examined the effect of 100 mg oral selumetinib twice daily in 28-day cycles versus oral temozolomide (200 mg/m(2)/d for 5 days, then 23 days off-...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume:
18
Issue:
2
Pages:
555-567
Publication date:
2012-01-01
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
Source identifiers:
237517

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP